Dr. Reddy’s Laboratories Ltd. has confirmed the effectiveness of its joint press release with the Global Antibiotic Research & Development Partnership Foundation (“GARDP”) regarding the approval of NUZOLVENCE® (zoliflodacin) by the Thai FDA. This approval follows the U.S. authorization by six months. The company clarified that this event does not constitute a material event requiring separate disclosure under SEBI Listing Regulations, emphasizing their commitment to timely reporting of significant information.
Regulatory Approval for Gonorrhea Treatment
Dr. Reddy’s Laboratories Ltd. has provided a clarification regarding a news item published in Business Standard. The company confirmed that a news article on July 28, 2026, with the headline “Dr Reddys antibiotic gets Thailand approval six months after US nod”, accurately reflects the situation. This pertains to the approval of the drug NUZOLVENCE® (zoliflodacin) by the Thai FDA.
Joint Press Release Confirmation
In connection with the news, Dr. Reddy’s Laboratories Ltd. stated that the headline is correct. The company issued a joint press release with the Global Antibiotic Research & Development Partnership Foundation (“GARDP”) on July 27, 2026. The press release was titled “Thai FDA approves NUZOLVENCE® (zoliflodacin) just six months after US authorization.” This signifies a significant step in the global rollout of the new treatment.
Disclosure Compliance
The company also clarified that this development, while significant, does not constitute a material event or information requiring a separate disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dr. Reddy’s Laboratories Ltd. reiterated its commitment to making timely disclosures of all events and information considered material and requiring disclosure under the applicable regulations. This confirmation ensures transparency and adherence to regulatory requirements.
Source: BSE
